Market Place
Sourcing Support
Oculis Publishes Transactions by Managers
09 Jun 2025 //
GLOBENEWSWIRE
Oculis Publishes Results of 2025 Annual General Meeting
05 Jun 2025 //
GLOBENEWSWIRE
Oculis Publishes Transactions by Managers
03 Jun 2025 //
GLOBENEWSWIRE
Oculis to Participate in Upcoming June Investor Conferences
03 Jun 2025 //
GLOBENEWSWIRE
Oculis Publishes Invitation to the Annual General Meeting
09 May 2025 //
GLOBENEWSWIRE
Oculis Reports Q1 Financial Results and Provides Company Update
08 May 2025 //
GLOBENEWSWIRE
Oculis Reports Q1 2025 Financial Results and Company Update
08 May 2025 //
GLOBENEWSWIRE
Oculis to Present at Upcoming May Investor Conferences
07 May 2025 //
GLOBENEWSWIRE
Oculis to Present Late-Stage Pipeline at Ophthalmology Conference
01 May 2025 //
GLOBENEWSWIRE
Oculis Updates Share Capital
25 Apr 2025 //
GLOBENEWSWIRE
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
17 Apr 2025 //
GLOBENEWSWIRE
Oculis Completes Enrollment in Ph 3 Trial in Diabetic Macular Edema
10 Apr 2025 //
GLOBENEWSWIRE
Oculis Publishes Transactions by Managers
09 Apr 2025 //
GLOBENEWSWIRE
Oculis to Host In-Person and Virtual R&D Day on Business Updates
01 Apr 2025 //
GLOBENEWSWIRE
Oculis Publishes Managerial Transactions Notifications
20 Mar 2025 //
GLOBENEWSWIRE
Oculis Publishes Notifications of Managerial Transactions
14 Mar 2025 //
GLOBENEWSWIRE
Oculis Reports Q4 and Full Year 2024 Financial Results
11 Mar 2025 //
GLOBENEWSWIRE
Oculis to Present at Upcoming March Investor Conference
05 Mar 2025 //
GLOBENEWSWIRE
Oculis Publishes Managerial Transactions Notification
03 Mar 2025 //
GLOBENEWSWIRE
Oculis Prices $100M Oversubscribed Offering Of Ordinary Shares
13 Feb 2025 //
GLOBENEWSWIRE
Oculis Publishes Notifications Of Transactions By Managers
07 Feb 2025 //
GLOBENEWSWIRE
Oculis updates share capital for its existing at market
31 Jan 2025 //
GLOBENEWSWIRE
Oculis Publishes Notification of Major Changes in Voting Rights
21 Jan 2025 //
GLOBENEWSWIRE
Oculis Publishes Notification of Major Changes in Voting Rights
20 Jan 2025 //
GLOBENEWSWIRE
Oculis peptidomimetic helps protect eyes from nerve inflammation
06 Jan 2025 //
FIERCE BIOTECH
Oculis OCS-05 Trial Shows Safety, Efficacy In Optic Neuritis
06 Jan 2025 //
GLOBENEWSWIRE
Oculis Publishes Notification of Major Changes in Voting Rights
03 Jan 2025 //
GLOBENEWSWIRE
Oculis Transactions by Managerial Responsibility Notifications
06 Dec 2024 //
GLOBENEWSWIRE
Oculis Publishes Notifications Of Transactions By Management
29 Nov 2024 //
GLOBENEWSWIRE
Oculis Publishes Managerial Transaction Notification
27 Nov 2024 //
GLOBENEWSWIRE
Oculis to Present at the Stifel 2024 Healthcare Conference
13 Nov 2024 //
GLOBENEWSWIRE
Oculis Reports Q3 2024 Financial Results & Company Updates
07 Nov 2024 //
GLOBENEWSWIRE
Oculis Accelerates Enrollment In DIAMOND Phase 3 Trials Of OCS-01
21 Oct 2024 //
GLOBENEWSWIRE
Oculis’ Diamond Phase 3 Program To Be Presented At Innovate Retina
15 Oct 2024 //
GLOBENEWSWIRE
Oculis Appoints Daniel S. Char as Chief Legal Officer
02 Oct 2024 //
GLOBENEWSWIRE
Oculis And EURETINA Announce Ramin Tadayoni Award Winner
19 Sep 2024 //
GLOBENEWSWIRE
Oculis to Present at Upcoming September Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error
28 Aug 2024 //
BIOSPACE
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
27 Aug 2024 //
GLOBENEWSWIRE
Oculis Publishes Consolidated Q2 Financial Statements and MD&A
27 Aug 2024 //
GLOBENEWSWIRE
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
15 Aug 2024 //
GLOBENEWSWIRE
Oculis Appoints Dr. Sharon Klier as Chief Development Officer
15 Aug 2024 //
CONTRACT PHARMA
Oculis To Participate In H.C. Wainwright Ophthalmology Conference
30 Jul 2024 //
GLOBENEWSWIRE
Oculis and EURETINA Announces the Ramin Tadayoni Award
27 Jun 2024 //
GLOBENEWSWIRE
Oculis Reports Positive Licaminlimab Dry Eye Phase 2b Trial Data
10 Jun 2024 //
GLOBENEWSWIRE
Oculis sees promise in dry eye disease subgroup, plans phase 3
10 Jun 2024 //
FIERCE BIOTECH
Oculis: Managerial Transactions Notifications Published
04 Jun 2024 //
GLOBENEWSWIRE
Oculis Announces Board And Advisory Board Appointments After 2024 AGM
30 May 2024 //
GLOBENEWSWIRE
Oculis updates share capital for its existing at-the-market offering program
17 May 2024 //
GLOBENEWSWIRE
Oculis OCS-05 Acute Optic Neuritis Phase 2 Enrollment Complete
08 May 2024 //
GLOBENEWSWIRE
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08 May 2024 //
GLOBENEWSWIRE
Oculis Publishes Invitation to the Annual General Meeting
06 May 2024 //
GLOBENEWSWIRE
Oculis to Present at Bank of America Global Healthcare Conference
06 May 2024 //
GLOBENEWSWIRE
Oculis Publishes Invitation to the Annual General Meeting
29 Apr 2024 //
GLOBENEWSWIRE
Oculis Registered Direct Offering Close, Nasdaq Iceland Trading
22 Apr 2024 //
GLOBENEWSWIRE
Oculis $59M Offering, Nasdaq Iceland Listing
11 Apr 2024 //
GLOBENEWSWIRE
Oculis Appoints Snehal Shah as President of R&D
10 Apr 2024 //
GLOBENEWSWIRE
Oculis to Participate at Upcoming April Investor Conferences
04 Apr 2024 //
GLOBENEWSWIRE
Oculis Reports Q4 and Full Year 2023 Financial Results and Update
18 Mar 2024 //
GLOBENEWSWIRE
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials
28 Feb 2024 //
GLOBENEWSWIRE
